Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
dubermatinib (TP-0903)
i
Other names:
TP-0903, TP 0903, TP0903
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(13)
News
Trials
Company:
Sumitomo Pharma
Drug class:
AXL inhibitor
Related drugs:
‹
BGB324 (26)
AVB-500 (4)
MGCD265 (4)
ONO-7475 (3)
AB-329 (2)
BPI-9016M (2)
JRF104 (2)
KC1036 (1)
AX-0085 (0)
CTS2016 (0)
INCB81776 (0)
PF-07265807 (0)
RXDX-106 (0)
S-49076 (0)
SLC-391 (0)
Q702 (0)
SKI-G-801 (0)
BGB149 (0)
BGB324 (26)
AVB-500 (4)
MGCD265 (4)
ONO-7475 (3)
AB-329 (2)
BPI-9016M (2)
JRF104 (2)
KC1036 (1)
AX-0085 (0)
CTS2016 (0)
INCB81776 (0)
PF-07265807 (0)
RXDX-106 (0)
S-49076 (0)
SLC-391 (0)
Q702 (0)
SKI-G-801 (0)
BGB149 (0)
›
Associations
(13)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors (NCT02729298)
Phase 1
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Completed
Phase 1
Sumitomo Pharma America, Inc.
Completed
Last update posted :
11/14/2023
Initiation :
12/14/2016
Primary completion :
06/29/2022
Completion :
06/29/2022
KRAS
|
KRAS mutation • BRAF mutation • NRAS mutation
|
dubermatinib (TP-0903)
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia (NCT04518345)
Phase 1b/2
Uma Borate
Uma Borate
Completed
Phase 1b/2
Uma Borate
Completed
Last update posted :
02/06/2023
Initiation :
11/05/2020
Primary completion :
10/13/2021
Completion :
12/22/2021
FLT3 • CD4
|
FLT3-ITD mutation
|
azacitidine • dubermatinib (TP-0903)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login